Market Closed -
Nasdaq
01:00:00 2024-07-03 pm EDT
|
5-day change
|
1st Jan Change
|
28.41
USD
|
-1.59%
|
|
-3.33%
|
+5.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,338
|
12,884
|
10,168
|
2,786
|
3,283
|
3,477
|
-
|
-
|
Enterprise Value (EV)
1 |
7,338
|
11,896
|
10,370
|
2,912
|
3,255
|
3,729
|
3,957
|
4,138
|
P/E ratio
|
-93
x
|
-49.6
x
|
-25
x
|
-4.24
x
|
-6.32
x
|
-8.94
x
|
-9.64
x
|
-10.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
34.2
x
|
44.9
x
|
27.2
x
|
6.2
x
|
5.82
x
|
5.11
x
|
4.28
x
|
3.51
x
|
EV / Revenue
|
34.2
x
|
41.5
x
|
27.8
x
|
6.48
x
|
5.77
x
|
5.48
x
|
4.87
x
|
4.17
x
|
EV / EBITDA
|
-103
x
|
-140
x
|
-26.7
x
|
-5.84
x
|
-7.46
x
|
-12.3
x
|
-14.6
x
|
-17.2
x
|
EV / FCF
|
-111
x
|
-84.9
x
|
-36.5
x
|
-7.53
x
|
-9.42
x
|
-12.6
x
|
-15.2
x
|
-18
x
|
FCF Yield
|
-0.9%
|
-1.18%
|
-2.74%
|
-13.3%
|
-10.6%
|
-7.92%
|
-6.59%
|
-5.57%
|
Price to Book
|
9.23
x
|
9.95
x
|
15.8
x
|
46.4
x
|
20.7
x
|
-35.1
x
|
-10.7
x
|
-7.42
x
|
Nbr of stocks (in thousands)
|
93,906
|
99,972
|
101,656
|
102,436
|
121,380
|
122,369
|
-
|
-
|
Reference price
2 |
78.14
|
128.9
|
100.0
|
27.20
|
27.05
|
28.41
|
28.41
|
28.41
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
214.4
|
286.7
|
373.7
|
449.5
|
563.9
|
680.2
|
812.7
|
991.5
|
EBITDA
1 |
-70.96
|
-85.18
|
-388.7
|
-498.9
|
-436.3
|
-303.2
|
-271.2
|
-240.9
|
EBIT
1 |
-82.37
|
-255
|
-411
|
-544.4
|
-564.7
|
-384.6
|
-357.4
|
-287.7
|
Operating Margin
|
-38.42%
|
-88.92%
|
-110%
|
-121.1%
|
-100.14%
|
-56.55%
|
-43.97%
|
-29.02%
|
Earnings before Tax (EBT)
1 |
-69.72
|
-245.9
|
-384.5
|
-653.4
|
-478.8
|
-387.6
|
-343.2
|
-302
|
Net income
1 |
-75.65
|
-253.8
|
-405.7
|
-654.6
|
-479.4
|
-384.7
|
-336.5
|
-299.8
|
Net margin
|
-35.29%
|
-88.51%
|
-108.57%
|
-145.61%
|
-85.02%
|
-56.56%
|
-41.4%
|
-30.24%
|
EPS
2 |
-0.8400
|
-2.600
|
-4.000
|
-6.410
|
-4.280
|
-3.179
|
-2.949
|
-2.609
|
Free Cash Flow
1 |
-65.85
|
-140.1
|
-284.1
|
-386.9
|
-345.5
|
-295.3
|
-260.7
|
-230.5
|
FCF margin
|
-30.72%
|
-48.86%
|
-76.02%
|
-86.07%
|
-61.26%
|
-43.42%
|
-32.08%
|
-23.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
108.1
|
96.1
|
109.1
|
117.4
|
126.9
|
128.7
|
137.2
|
143
|
155.1
|
168.5
|
162.6
|
169.1
|
181.1
|
189.2
|
197.4
|
EBITDA
1 |
-92.12
|
-111.6
|
-120
|
-122.6
|
-133.3
|
-123.4
|
-108.1
|
-101.8
|
-102.9
|
-88.48
|
-77.82
|
-77.73
|
-79.21
|
-77.3
|
-76.15
|
EBIT
1 |
-98.21
|
-123.3
|
-130.3
|
-144.6
|
-146.1
|
-134.1
|
-119.6
|
-113.5
|
-197.5
|
-99.68
|
-102.9
|
-99.41
|
-96.42
|
-97.83
|
-98.27
|
Operating Margin
|
-90.84%
|
-128.34%
|
-119.4%
|
-123.16%
|
-115.15%
|
-104.15%
|
-87.22%
|
-79.38%
|
-127.38%
|
-59.16%
|
-63.28%
|
-58.8%
|
-53.25%
|
-51.7%
|
-49.78%
|
Earnings before Tax (EBT)
1 |
-72.3
|
-123.3
|
-229
|
-161.9
|
-139.3
|
-133.3
|
-72.28
|
-85.61
|
-187.6
|
-114.6
|
-101.5
|
-98.4
|
-97.11
|
-92.84
|
-97.01
|
Net income
1 |
-90.91
|
-123.2
|
-229.4
|
-162
|
-139.9
|
-133.5
|
-72.77
|
-86.1
|
-187
|
-115
|
-96.8
|
-93.56
|
-90.93
|
-90.6
|
-90.84
|
Net margin
|
-84.09%
|
-128.23%
|
-210.21%
|
-137.98%
|
-110.28%
|
-103.74%
|
-53.06%
|
-60.2%
|
-120.63%
|
-68.24%
|
-59.54%
|
-55.34%
|
-50.21%
|
-47.88%
|
-46.02%
|
EPS
2 |
-0.8900
|
-1.210
|
-2.250
|
-1.580
|
-1.360
|
-1.300
|
-0.6700
|
-0.7300
|
-1.580
|
-0.9400
|
-0.7897
|
-0.7608
|
-0.7414
|
-0.7368
|
-0.7413
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/23/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/9/23
|
8/3/23
|
11/6/23
|
2/22/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
202
|
126
|
-
|
253
|
481
|
661
|
Net Cash position
1 |
-
|
989
|
-
|
-
|
28.7
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.5198
x
|
-0.2529
x
|
-
|
-0.8331
x
|
-1.773
x
|
-2.745
x
|
Free Cash Flow
1 |
-65.9
|
-140
|
-284
|
-387
|
-345
|
-295
|
-261
|
-230
|
ROE (net income / shareholders' equity)
|
-11.8%
|
-24.2%
|
-41.7%
|
-186%
|
-438%
|
-122%
|
-48.6%
|
-9%
|
ROA (Net income/ Total Assets)
|
-9.76%
|
-15.7%
|
-18.1%
|
-34.3%
|
-28.2%
|
-15.7%
|
-16.6%
|
-12.5%
|
Assets
1 |
775
|
1,617
|
2,238
|
1,907
|
1,698
|
2,450
|
2,027
|
2,408
|
Book Value Per Share
2 |
8.470
|
13.00
|
6.340
|
0.5900
|
1.300
|
-0.8100
|
-2.670
|
-3.830
|
Cash Flow per Share
2 |
-0.5200
|
-1.070
|
-2.060
|
-3.030
|
-2.900
|
-1.970
|
-1.170
|
0.4400
|
Capex
1 |
18.7
|
36.2
|
75
|
77.5
|
20.5
|
44.5
|
51.3
|
45.9
|
Capex / Sales
|
8.73%
|
12.62%
|
20.08%
|
17.23%
|
3.63%
|
6.54%
|
6.31%
|
4.63%
|
Announcement Date
|
2/24/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
28.41
USD Average target price
37.45
USD Spread / Average Target +31.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +5.03% | 3.48B | | -41.62% | 7.97B | | -9.10% | 2.07B | | -29.56% | 1.83B | | -21.96% | 1.64B | | +6.72% | 928M | | -9.17% | 690M | | -30.82% | 500M | | -16.50% | 248M | | -14.72% | 173M |
Bio Diagnostics & Testing
|